News Releases
Sep 2 2021
Avid Bioservices to Participate at Upcoming Investor Conferences
Sep 1 2021
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2022 After Market Close on September 8, 2021
Jul 1 2021
Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D., to Board of Directors
Jun 29 2021
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Developments
Jun 22 2021
Avid Bioservices to Report Financial Results For Quarter and Fiscal Year Ended April 30, 2021 After Market Close on June 29, 2021
May 25 2021
Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics’ ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)
Apr 15 2021
Avid Bioservices Announces Completion of Redemption of Series E Convertible Preferred Stock
Mar 17 2021
Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
Mar 10 2021
Avid Bioservices, Inc. Announces Pricing of $125 Million Offering of Exchangeable Senior Notes
Mar 8 2021
Avid Bioservices, Inc. Announces Proposed $125 Million Offering of Exchangeable Senior Notes